[go: up one dir, main page]

AR075383A1 - Derivados de triazolo[4,3-b]piridazina - Google Patents

Derivados de triazolo[4,3-b]piridazina

Info

Publication number
AR075383A1
AR075383A1 ARP100100350A ARP100100350A AR075383A1 AR 075383 A1 AR075383 A1 AR 075383A1 AR P100100350 A ARP100100350 A AR P100100350A AR P100100350 A ARP100100350 A AR P100100350A AR 075383 A1 AR075383 A1 AR 075383A1
Authority
AR
Argentina
Prior art keywords
alkyl
cr3r4
heteroatoms
independently selected
identically
Prior art date
Application number
ARP100100350A
Other languages
English (en)
Inventor
Robert Hugh Bradbury
Alfred Arthur Rabow
Gregory Richard Carr
Korupoju Srinivasa Rao
Harikrishna Tumma
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR075383A1 publication Critical patent/AR075383A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Se refiere a procesos para la preparacion de dichos compuestos, composiciones farmacéuticas que los contienen y su uso en el tratamiento de afecciones asociadas con el receptor de androgenos, en particular el cáncer de prostata. Reivindicacion 1: Un compuesto caracterizado porque es de Formula 1, o una sal farmacéuticamente aceptable del mismo: en donde R1 representa haloalquilo C1-4; k representa 0, 1 o 2: n y p independientemente representan 1 o 2: Y representa N, C, CH o COH; la línea punteada representa un enlace simple cuando Y es N, CH o COH; la línea punteada representa un enlace doble cuando Y es C, L1 es un enlace directo y J es indolilo pirrolopiridinilo: L1 representa un enlace directo,-(CR3R4)t-, -(CR3R4)v-O-(CR3R4)v-, -N(R5)-(CH2)q-, -S-, -S(O)- o S(O)2-; R3 y R4, de forma idéntica o diferente en cada aparicion, representan hidrogeno o metilo; R5 representa hidrogeno o metilo: q, de forma idéntica o diferente en cada aparicion, representa 0, 1, 2, 3 o 4; t representa 1, 2 o 3; v, de forma idéntica o diferente en cada aparicion, representa 0, 1 o 2; j representa: arilo; cicloalquilo C3-6; un anillo heterocíclico de 4, 5, 6 o 7 miembros monocíclico que comprende 1, 2 o 3 heteroátomos que se seleccionan independientemente de O, N o S; Un anillo heteroarilo monocíclico de 5 o 6 miembros que comprende 1, 2, 3 o 4 heteroátomos que se seleccionan independientemente de O, N o S; o un sistema de anillos heteroarilo bicíclico de 9 o 10 miembros que comprende 1, 2, 3, 4 o 5 heteroátomos que se seleccionan independientemente de O, N o S; L2 representa un enlace directo. -(CR3R4)t-, -C(O)N(R5)-(CH2)q-, -C(O)N(R5)-(CH2)q- S(O)2-, -NR5C(O)-(CH2)q-, -C(O)-(CH2)q-, -O-(CR9R10)q-, -O-(CR3R4)q-NR5-(CH2)q-, -O-(CR3R4)q-C(O)NR5-(CH2)q-, -S-, -S(O)- o -S(O)2-; R9 y R10, de forma idéntica o diferente en cada aparicion, representan hidrogeno, metilo, etilo, isopropilo, ciclopropilo o metoximetilo: R2 representa: halo, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, carboxi, alcoxi C1-6, ciano, oxo, fluoroalquilo C1-6, hidroxi, animo, N-alquil C1-4amino o N,N-di-alquil C1-4amino; arilo, en donde el anillo arilo está opcionalmente sustituido por 1, 2 o 3 sustituyentes que se seleccionan de R6; un anillo heterocíclico de 4, 5, 6 o 7 miembros monocíclico que comprende 1, 2 o 3 heteroátomos que se seleccionan independientemente de O, N o S y en donde el anillo heterocíclico está opcionalmente sustituido por 1, 2 o 3 sustituyentes que se seleccionan de R6; un anillo heteroarilo de 5 o 6 miembros monocíclico que comprende 1, 2, 3 o 4 heteroátomos que se seleccionan independientemente de O, N o S y en donde el anillo heteroarilo está opcionalmente sustituido por 1, 2 o 3 sustituyentes que se seleccionan de R6: o un sistema de anillos heteroarilo bicíclico de 9 o 10 miembros que comprenden 1, 2, 3, 4 o 5 heteroátomos que se seleccionan independientemente de O, N o S y en donde el anillo heterocíclico está opcionalmente sustituido por 1, 2 o 3 sustituyentes que se seleccionan de R6; R6 representa amino, halo, alquilo C1-6, cicloalquilo C3-6, alquenilo C2-6, alquinilo C2-6, alcoxi C1-6, alcanoilo C2-6, alcoxi C1-6 alquilo C1-6, carboxi, ciano, oxo, fluoroalquilo C1-6, hidroxi, hidroxialquilo C1-6, alquil C1-6 sulfanilo, alquil C1-6 sulfinilo, alquil C1-6 sulfonilo, oxetan-3-ilcarbonilo, N-alquil C1-4 amino N,N-di-alquil C1-4 amino o -C(O)NR7R8 en donde R7 y R8 independientemente representan hidrogeno o metilo; y r representa 0, 1, 2 o 3.
ARP100100350A 2009-02-10 2010-02-09 Derivados de triazolo[4,3-b]piridazina AR075383A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15122109P 2009-02-10 2009-02-10
US18776609P 2009-06-17 2009-06-17

Publications (1)

Publication Number Publication Date
AR075383A1 true AR075383A1 (es) 2011-03-30

Family

ID=42115693

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100100350A AR075383A1 (es) 2009-02-10 2010-02-09 Derivados de triazolo[4,3-b]piridazina

Country Status (26)

Country Link
US (2) US8258140B2 (es)
EP (1) EP2396333B1 (es)
JP (1) JP5059977B2 (es)
KR (1) KR20110113755A (es)
CN (1) CN102388048B (es)
AR (1) AR075383A1 (es)
AU (1) AU2010212590B2 (es)
CA (1) CA2749926A1 (es)
CL (1) CL2011001920A1 (es)
CO (1) CO6410299A2 (es)
CR (1) CR20110427A (es)
CU (1) CU20110158A7 (es)
DO (1) DOP2011000258A (es)
EA (1) EA019647B1 (es)
EC (1) ECSP11011257A (es)
ES (1) ES2427917T3 (es)
IL (1) IL214112A0 (es)
MX (1) MX2011008452A (es)
NI (1) NI201100156A (es)
PE (1) PE20120603A1 (es)
SG (1) SG172986A1 (es)
SV (1) SV2011003993A (es)
TW (1) TW201033215A (es)
UY (1) UY32426A (es)
WO (1) WO2010092371A1 (es)
ZA (1) ZA201106625B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20120473A1 (es) * 2009-05-11 2012-05-27 Astrazeneca Ab [1,2,4]triazolo[4,3-b]piridazinas como ligandos del receptor de androgenos
AU2012321110B2 (en) * 2011-11-30 2014-10-23 Astrazeneca Ab Combination treatment
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms
HRP20202050T1 (hr) 2012-09-04 2021-02-19 Shanghai Hengrui Pharmaceutical Co., Ltd. Derivati imidazolina, postupci njihove pripreme i njihova medicinska primjena
WO2015042170A1 (en) 2013-09-17 2015-03-26 Wayne State University Compositions and uses of combinations of dim-related indoles and selected anti-androgen compounds
NO2719005T3 (es) 2014-07-28 2018-01-20
BR112017019453A2 (pt) 2015-03-13 2018-05-15 Forma Therapeutics Inc compostos e composições de alfa-cinamida como inibidores de hdac8
EP3285764B1 (en) 2015-03-31 2024-03-27 University of Vermont and State Agricultural College Triazolopyridazines for treating cryptosporidiosis
EP3824908A1 (en) 2015-04-10 2021-05-26 Capsugel Belgium NV Abiraterone acetate lipid formulations
US11664093B2 (en) * 2019-01-17 2023-05-30 The Board Of Trustees Of The University Of Illinois Extrapolative prediction of enantioselectivity enabled by computer-driven workflow, new molecular representations and machine learning
JP7183842B2 (ja) * 2019-02-08 2022-12-06 富士通株式会社 結合自由エネルギー計算の前処理方法、前処理装置及び前処理プログラム、並びに、結合自由エネルギーの算出方法
AU2020266604A1 (en) * 2019-05-02 2021-11-18 Constellation Pharmaceuticals, Inc. Modulators of TREX1
US20220218701A1 (en) * 2019-05-31 2022-07-14 United States Government As Represented By The Department Of Veterans Affairs Compositions and methods comprising endothelin a receptor antagonists and androgen therapies
TWI813106B (zh) * 2020-12-30 2023-08-21 財團法人工業技術研究院 雄性激素受體結合分子及其用途
WO2022266162A1 (en) 2021-06-16 2022-12-22 Celgene Corporation Azetidinyl compounds comprising a carboxylic acid group for the treatment of neurodegenerative diseases
WO2024137968A1 (en) * 2022-12-21 2024-06-27 Capulus Therapeutics, Llc Androgen receptor modulators and methods for their use

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE35956E (en) * 1991-01-09 1998-11-10 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
FR2693461B1 (fr) 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
US5411981A (en) * 1991-01-09 1995-05-02 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
AU719434B2 (en) 1996-02-13 2000-05-11 Astrazeneca Ab Quinazoline derivatives as VEGF inhibitors
ES2169355T3 (es) 1996-03-05 2002-07-01 Astrazeneca Ab Derivados de 4-anilinoquinazolina.
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
MXPA01008182A (es) 1999-02-10 2003-08-20 Astrazeneca Ab Derivados de quinazolina como inhibidores de angiotensina.
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
EP1289952A1 (en) 2000-05-31 2003-03-12 AstraZeneca AB Indole derivatives with vascular damaging activity
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
CA2411160A1 (en) 2000-07-07 2002-01-17 Angiogene Pharmaceuticals Limited Colchinol derivatives as vascular damaging agents
MXPA02012903A (es) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Derivados de colquinol como inhibidores de angiogenesis.
US7268230B2 (en) 2002-02-01 2007-09-11 Astrazeneca Ab Quinazoline compounds
US20040102360A1 (en) * 2002-10-30 2004-05-27 Barnett Stanley F. Combination therapy
US20050124625A1 (en) 2003-10-21 2005-06-09 Salvati Mark E. Piperazine derivatives and their use as modulators of nuclear hormone receptor function
US7388027B2 (en) 2004-03-04 2008-06-17 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
CN1597671A (zh) * 2004-07-20 2005-03-23 贵州大学 喹唑啉衍生物及制备方法和生物活性
AU2005292134B2 (en) * 2004-10-01 2010-12-23 Merck Sharp & Dohme Corp. Aminopiperidines as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
US7572807B2 (en) * 2005-06-09 2009-08-11 Bristol-Myers Squibb Company Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors
EP1963329B1 (en) * 2005-11-30 2013-01-23 Vertex Pharmaceuticals Incorporated Inhibitors of c-met and uses thereof
JP5230448B2 (ja) 2006-02-10 2013-07-10 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 選択的アンドローゲン受容体モジュレーターとして有用な新イミダゾロピラゾール誘導体
CA2642205C (en) 2006-02-10 2015-01-27 Janssen Pharmaceutica N.V. Bicyclic imidazole or thiadiazole heterocycles useful as selective androgen receptor modulators
CA2651979A1 (en) * 2006-05-30 2007-12-06 Pfizer Products Inc. Triazolopyridazine derivatives
AU2007279595A1 (en) 2006-08-04 2008-02-07 Takeda Pharmaceutical Company Limited Fused heterocyclic derivative and use thereof
CN101563339A (zh) * 2006-09-14 2009-10-21 阿斯利康(瑞典)有限公司 作为 p i 3 k和 m t o r抑制剂用于治疗增殖性疾病的 2 -苯并咪唑基 - 6 -吗啉代 - 4 - (氮杂环丁烷、吡咯烷、哌啶或氮杂)嘧啶衍生物
WO2008044033A1 (en) 2006-10-11 2008-04-17 Astrazeneca Ab Amide derivatives
BRPI0717317A2 (pt) * 2006-10-23 2013-10-22 Sgx Pharmaceuticals Inc Modularoes da proteína cinase triazalopiridazina
WO2008109104A1 (en) * 2007-03-07 2008-09-12 The Regents Of The University Of California Bivalent inhibitors of akt protein kinase
WO2009005675A1 (en) 2007-06-28 2009-01-08 Abbott Laboratories Novel triazolopyridazines
PA8792501A1 (es) * 2007-08-09 2009-04-23 Sanofi Aventis Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.
FR2919870B1 (fr) 2007-08-09 2014-05-16 Sanofi Aventis Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzothiazole et benzimidazole, procede, compositions pharmaceutiques et nouvelle utilisation comme inhibiteurs de cmet
EA017144B1 (ru) 2007-12-21 2012-10-30 Астразенека Аб N-содержащие бициклические производные для применения при лечении состояний, связанных с андрогенным рецептором
PE20120473A1 (es) 2009-05-11 2012-05-27 Astrazeneca Ab [1,2,4]triazolo[4,3-b]piridazinas como ligandos del receptor de androgenos

Also Published As

Publication number Publication date
UY32426A (es) 2010-09-30
ECSP11011257A (es) 2011-09-30
CR20110427A (es) 2011-09-21
JP2012517462A (ja) 2012-08-02
EA019647B1 (ru) 2014-05-30
IL214112A0 (en) 2011-08-31
CN102388048A (zh) 2012-03-21
WO2010092371A1 (en) 2010-08-19
CU20110158A7 (es) 2012-02-15
US20130203714A1 (en) 2013-08-08
SV2011003993A (es) 2012-01-06
AU2010212590A1 (en) 2011-08-04
PE20120603A1 (es) 2012-06-14
CA2749926A1 (en) 2010-08-19
US20100267699A1 (en) 2010-10-21
EP2396333A1 (en) 2011-12-21
EP2396333B1 (en) 2013-07-03
AU2010212590B2 (en) 2013-01-10
EA201101180A1 (ru) 2012-03-30
KR20110113755A (ko) 2011-10-18
ES2427917T3 (es) 2013-11-04
HK1164870A1 (en) 2012-09-28
TW201033215A (en) 2010-09-16
CL2011001920A1 (es) 2011-10-21
CN102388048B (zh) 2014-07-30
MX2011008452A (es) 2011-12-16
SG172986A1 (en) 2011-08-29
US8258140B2 (en) 2012-09-04
CO6410299A2 (es) 2012-03-30
DOP2011000258A (es) 2011-09-30
JP5059977B2 (ja) 2012-10-31
ZA201106625B (en) 2013-02-27
NI201100156A (es) 2012-03-19

Similar Documents

Publication Publication Date Title
AR075383A1 (es) Derivados de triazolo[4,3-b]piridazina
ES2666870T3 (es) Derivado de dispiropirrolidina
PE20220931A1 (es) Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina
AR127309A2 (es) Derivados de piridazinona
AR080865A1 (es) Derivados de espirotetrahidronaftaleno, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos para tratar enfermedades neurodegenerativas,tal como alzheimer.
ES2686501T3 (es) Pirazolo[1,5-a]piridinas sustituidas como inhibidores de la quinasa del receptor de tropomiosina (Trk)
AR084553A1 (es) DERIVADOS IMIDAZOLICOS HETEROCICLICOS INHIBIDORES DE b-SECRETASA, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y USO DE LOS MISMOS PARA TRATAR ENFERMEDADES NEURODEGENERATIVAS, EN PARTICULAR ALZHEIMER
AR067757A1 (es) Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales.
PE20190656A1 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1
AR083813A1 (es) Derivados de pirazol aminopirimidina como moduladores de lrrk2
AR074596A1 (es) Derivados de (3-oxo) piridazin-4-ilurea
AR059064A1 (es) Compuestos de tiazol, composiciones farmaceuticas que los contienen y usos en el tratamiento de enfermedades mediadas por la proteina quinasa b(pkb), tales como cancer.
AR078786A1 (es) Derivados de la cromenona
AR070463A1 (es) Compuestos de amina y eter que modulan el receptor cb2
ES2620668T3 (es) Derivados de amidas y sulfonamidas amido espirocíclicas
AR064608A1 (es) Derivados de pirazolo-quinazolina sustituidos, composiciones farmaceuticas que los contienen. proceso para su preparacion y uso de los mismos como agentes anticancer.
AR077434A1 (es) Compuestos para la reduccion de produccion de beta - amiloide
AR085960A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
AR107321A1 (es) Compuestos antiproliferativos, y sus composiciones farmacéuticas y usos
AR075253A1 (es) Pirimidinas fusionadas, procesos de preparacion y composiciones farmaceuticas que los contiene.
AR102213A1 (es) Inhibidores de la biosíntesis de sulfato de heparano para el tratamiento de enfermedades
AR087328A1 (es) Derivados de imidazo[1,2-b]piridazina e imidazo[4,5-b]piridina como inhibidores de jak
AR098666A1 (es) Compuestos de biarilacetamida y sus métodos de uso
AR071856A1 (es) Derivados de indazoles sustituidos con fenilo o piridinilo, un proceso para su preparacion, una composicion farmaceutica que los comprende y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por el receptor de glucocorticoides.
AR087711A1 (es) Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y uso de los mismos para el tratamiento de trastornos neurodegenerativos

Legal Events

Date Code Title Description
FB Suspension of granting procedure